Chest imaging
Case TypeClinical Cases
Authors
Sandra C M1, Breman Anil Peethambar2
Patient60 years, male
A 60-year-old male patient arrived complaining of worsening fever, breathlessness and non-productive cough for the past 1 month. There was no history of weight loss, chills, hemoptysis, diabetes mellitus, steroid use or malignancy. Physical examination revealed bilateral scattered crepitation. His fasting blood sugar was found to be 286 mg/dl.
Computed tomography (CT) revealed 3 nodules with irregular margins noted in the lateral segment of right middle lobe, superior segment of right lower lobe and superior lingular segment of left lower lobe. These lesions showed central ground glass shadows with a peripheral rim of consolidation giving the appearance of a reverse halo sign (RHS) (Figure 1). All lesions showed secondary cavitation and, irregular, intersecting strands within it, giving it the classic appearance of a bird’s nest sign (Figure 3a & 3b).
Another 8.1* 6.2 * 11.9 cm cavity was noted in the superior segment of left lower lobe with thick walls and an air-fluid level within, indicating a lung abscess (Figure 2a & 2b). Following contrast administration, there is very minimal enhancement of the cavity wall seen. The rest of the lesions were non-enhancing. A few enlarged paratracheal lymph nodes were seen within the mediastinum.
Pulmonary mucormycosis (PM) is an uncommon, opportunistic angioinvasive infection caused by a fungus belonging to the order Mucorales [1][2]. PM is the second most common manifestation of mucormycosis after rhino-orbital-cerebral infection. Prognosis of PM is poor with mortality approaching 75% [3]. Common risk factors include hematologic malignancies, organ and stem cell transplant, prolonged steroid therapy and diabetes. Symptoms comprise fever, dyspnoea, cough and haemoptysis [4][5].
Radiological features in PM are nonspecific. Lobar and segmental consolidation is the most common imaging finding in a chest radiograph followed by single or multiple nodules and masses which may have a surrounding ground glass halo [6]. The extent of PM is best determined by HRCT. Mark M Hammer et al who reviewed CT studies of 30 patients concluded that nodules were present in 20%, consolidations were present in 57%, RHS in 60%, perilesional halo in 53% and cavitation in 10% of patients [7].
The clinical and radiologic manifestations of PM resemble those of invasive pulmonary aspergillosis (IPA) [8]. However, it is important to distinguish between the two as the treatments involved are different. Various studies have identified a RHS to be associated with PM than with IPA [6] [9-11]. J Vogel conducted a study in which bird’s nest sign could be identified in CT in 22% of patients [12]. Abscess formation was noted in 13% of PM cases in a study conducted by Murphy and Miller [13]. The case presented here showed RHS, bird’s nest sign and abscess formation, all favouring a diagnosis of PM.
Common bacterial infections such as staphylococcus aureus, Klebsiella and mycobacterium, septic emboli, granulomatosis with polyangitis, rheumatoid nodules also present as cavitary pulmonary lesions [14]. Unless surgery is contraindicated, the recommended therapy for PM is early surgical debridement in conjunction with early amphotericin B therapy [15]. Finding of characteristic hyphae in the biopsy specimen remains the gold standard for diagnosis of PM. The patient in this case underwent bronchoscopy and BAL specimen was sent for culture which confirmed the presence of zygomycetes species. The patient was started on injection liposomal Amphotericin B 350 mg in 5 % dextrose over 3 hours following radiological diagnosis.
Teaching points: Imaging findings of PM are nonspecific. However, radiologists should look out for RHS, bird’s nest sign, features of hyphal invasion of arteries along with immunocompromised status of the patient which are more often associated with PM.
Written informed patient consent for publication has been obtained.
[1] Lin E, Moua T, Limper AH. Pulmonary mucormycosis: clinical features and outcomes. Infection. 2017 Aug;45(4):443-448. doi: 10.1007/s15010-017-0991-6. Epub 2017 Feb 20. PMID: 28220379.
[2] Roden MM, Zaoutis TE, Buchanan WL, Knudsen TA, Sarkisova TA, Schaufele RL, Sein M, Sein T, Chiou CC, Chu JH, Kontoyiannis DP, Walsh TJ. Epidemiology and outcome of zygomycosis: a review of 929 reported cases. Clin Infect Dis. 2005 Sep 1;41(5):634-53. doi: 10.1086/432579. Epub 2005 Jul 29. PMID: 16080086.
[3] Petrikkos G, Skiada A, Lortholary O, Roilides E, Walsh TJ, Kontoyiannis DP. Epidemiology and clinical manifestations of mucormycosis. Clin Infect Dis. 2012 Feb;54 Suppl 1:S23-34. doi: 10.1093/cid/cir866. PMID: 22247442.
[4] Rammaert B, Lanternier F, Zahar JR, Dannaoui E, Bougnoux ME, Lecuit M, Lortholary O. Healthcare-associated mucormycosis. Clin Infect Dis. 2012 Feb;54 Suppl 1:S44-54. doi: 10.1093/cid/cir867. PMID: 22247444.
[5] Neofytos D, Treadway S, Ostrander D, Alonso CD, Dierberg KL, Nussenblatt V, Durand CM, Thompson CB, Marr KA. Epidemiology, outcomes, and mortality predictors of invasive mold infections among transplant recipients: a 10-year, single-center experience. Transpl Infect Dis. 2013 Jun;15(3):233-42. doi: 10.1111/tid.12060. Epub 2013 Feb 21. PMID: 23432974; PMCID: PMC3664270.
[6] Agrawal R, Yeldandi A, Savas H, Parekh ND, Lombardi PJ, Hart EM. Pulmonary Mucormycosis: Risk Factors, Radiologic Findings, and Pathologic Correlation. Radiographics. 2020 May-Jun;40(3):656-666. doi: 10.1148/rg.2020190156. Epub 2020 Mar 20. PMID: 32196429.
[7] Hammer MM, Madan R, Hatabu H. Pulmonary Mucormycosis: Radiologic Features at Presentation and Over Time. AJR Am J Roentgenol. 2018 Apr;210(4):742-747. doi: 10.2214/AJR.17.18792. Epub 2018 Feb 22. PMID: 29470162.
[8] Chamilos G, Marom EM, Lewis RE, Lionakis MS, Kontoyiannis DP. Predictors of pulmonary zygomycosis versus invasive pulmonary aspergillosis in patients with cancer. Clin Infect Dis. 2005 Jul 1;41(1):60-6. doi: 10.1086/430710. Epub 2005 May 24. PMID: 15937764.
[9] Wahba H, Truong MT, Lei X, Kontoyiannis DP, Marom EM. Reversed halo sign in invasive pulmonary fungal infections. Clin Infect Dis. 2008 Jun 1;46(11):1733-7. doi: 10.1086/587991. PMID: 18419427.
[10] Legouge C, Caillot D, Chrétien ML, Lafon I, Ferrant E, Audia S, Pagès PB, Roques M, Estivalet L, Martin L, Maitre T, Bastie JN, Dalle F. The reversed halo sign: pathognomonic pattern of pulmonary mucormycosis in leukemic patients with neutropenia? Clin Infect Dis. 2014 Mar;58(5):672-8. doi: 10.1093/cid/cit929. Epub 2013 Dec 18. PMID: 24352351.
[11] Jung J, Kim MY, Lee HJ, Park YS, Lee SO, Choi SH, Kim YS, Woo JH, Kim SH. Comparison of computed tomographic findings in pulmonary mucormycosis and invasive pulmonary aspergillosis. Clin Microbiol Infect. 2015 Jul;21(7):684.e11-8. doi: 10.1016/j.cmi.2015.03.019. Epub 2015 Apr 13. PMID: 25882362.
[12] Horger M, Hebart H, Schimmel H, Vogel M, Brodoefel H, Oechsle K, Hahn U, Mittelbronn M, Bethge W, Claussen CD. Disseminated mucormycosis in haematological patients: CT and MRI findings with pathological correlation. Br J Radiol. 2006 Sep;79(945):e88-95. doi: 10.1259/bjr/16038097. PMID: 16940368.
[13] Murphy RA, Miller WT Jr. Pulmonary mucormycosis. Semin Roentgenol. 1996 Jan;31(1):83-7. doi: 10.1016/s0037-198x(96)80043-5. PMID: 8838948.
[14] Parkar AP, Kandiah P. Differential Diagnosis of Cavitary Lung Lesions. J Belg Soc Radiol. 2016 Nov 19;100(1):100. doi: 10.5334/jbr-btr.1202. PMID: 30151493; PMCID: PMC6100641.
[15] Fernandez JF, Maselli DJ, Simpson T, Restrepo MI. Pulmonary mucormycosis: what is the best strategy for therapy? Respir Care. 2013 May;58(5):e60-3. doi: 10.4187/respcare.02106. PMID: 23107233; PMCID: PMC4066629.
URL: | https://eurorad.org/case/18273 |
DOI: | 10.35100/eurorad/case.18273 |
ISSN: | 1563-4086 |
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.